Target intelligence / Profile preview

Organic anion transporter 7 (OAT7)

Target
OAT7
Molecular classification
Transporter, Organic anion transporter (OAT subfamily), Major facilitator superfamily (MFS), Solute carrier family 22 (SLC22)
01

Overview

Organic anion transporter 7 (OAT7; SLC22A9) is a membrane protein found predominantly on the sinusoidal (basolateral) membrane of hepatocytes in the human liver. It specifically transports sulfate conjugates of endogenous steroids (estrone 3-sulfate, dehydroepiandrosterone sulfate), xenobiotics, and the statin drug pravastatin into liver cells. The transporter operates an exchange mechanism with short-chain fatty acids such as butyrate, acting independently of sodium. It is not inhibited by probenecid (unlike other OATs) and is activated by SCFAs. OAT7 is implicated in hepatic drug uptake, hormone metabolism, and is associated with mismatch repair cancer syndrome. While its physiological and pathological roles are still being elucidated, OAT7 may be clinically important in pharmacokinetics and therapeutic modulation of drugs whose hepatic uptake relies on organic anion transport, particularly when other hepatic OATPs are compromised.

Other names
SLC22A9hOAT4OAT7UST3OAT4FLJ23666UST3HOrganic anion/short-chain fatty acid exchangerOrganic anion transporter 4
02

Mechanism of action

Transport/exchange of organic anion substrates (including sulfated steroids and pravastatin) into hepatocytes, often exchanging with short-chain fatty acids such as butyrate or valerate

03

Biological functions

Organic anion transmembrane transport (mainly sulfate conjugates of steroids and drugs)Short-chain fatty acid exchange (e.g., butyrate, valerate)Hormone transport (esterified steroids like estrone 3-sulfate and DHEA sulfate)Drug disposition (pravastatin transport)
04

Disease associations

Cancer (particularly mismatch repair cancer syndrome/Lynch syndrome, due to its transport properties in liver and possible roles in hormone metabolism)Persistent fetal circulation syndrome (reported association)Other (may impact statin pharmacokinetics and liver disease risk)
05

Safety considerations

Limited data on direct therapeutic safety concerns for OAT7-targeting drugsDrug interactions could alter liver drug disposition (especially for statins), but OAT7 is not regulated in current FDA/EMA guidelines
06

Interacting drugs

Pravastatin

2 more in the full profile.

07

Biomarkers

Genetic polymorphisms (SNPs may impact drug transport and disease; not yet validated for clinical use in patient selection)Null (no established clinical biomarkers)

Beyond the preview

Go deeper on Organic anion transporter 7 (OAT7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Organic anion transporter 7 (OAT7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call